Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference
Get Alerts CLVS Hot Sheet
Join SI Premium – FREE
BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 10:00 a.m. Pacific time. The conference will be held at the Encore hotel in Las Vegas.
A live webcast of the presentation can be accessed through the investor relations section of the Company’s website at www.clovisoncology.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the US, Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado; please visit www.clovisoncology.com for more information, including additional office locations in the US and Europe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005142/en/
Anna Sussman
(303) 625-5022
[email protected]
Breanna Burkart
(303) 625-5023
[email protected]
Source: Clovis Oncology, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Yara reports increased deliveries, lower prices and reduced GHG emission intensity in 1Q
- Information relating to the total number of voting rights and shares making up the share capital at 26 April 2024 – post blocs acquisition by the Consortium
- GXO helps Virgin Media O2 cut single use plastic
Create E-mail Alert Related Categories
Business Wire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!